Abstract

Objective To compare the clinical outcomes of low-dose rabbit antithymocyte globulin (rATG) vs basiliximab as induction therapy in recipients of ABO-incompatible kidney transplantation (ABOi-KT). Methods Retrospective analysis was conducted for e the clinical data of 40 ABOi-KT recipients between March 2017 and March 2019. 17 recipients of them received induction therapy with basiliximab (basiliximab group) while another 23 recipients received low-dose rATG (rATG group, rATG 25 mg/d×3 d). During a median follow-up period of 282 days, the data of serum creatinine and eGFR at 1 week and 1 month, graft survival rate and complication rate of two groups were compared. Results No significant difference existed in age, gender, dialytic modality/duration, blood groups of recipients, HLA mis-match, blood group antibody titers, dose of rituximab, blood groups of donors or donor age (P>0.05). The times of double filtration plasmapheresis in Basiliximab group were more (P 0.05). No significant difference existed in graft survival rate. No significant difference existed in rate of acute rejection, parvovirus B19 infection, urinary tract infection or hematoma. Conclusions Low-dose of rATG is as effective as basiliximab for ABOi-KT recipients. And rATG does not increase the rate of infection. Key words: Kidney transplantation; ABO blood group; Incompatible; Living donor; Rabbit antithymocyte globulin; Basiliximab

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.